Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

William Blair analysts led by Matt Phipps, who rate Incyte at Outperform, called the news disappointing. They highlighted ...

Nvidia helped pull U.S. stock indexes higher after they stumbled in the morning on worries about escalations in the ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

GSA Capital Partners LLP increased its stake in Allakos Inc. (NASDAQ:ALLK – Free Report) by 11.9% in the 3rd quarter, ...

Incyte tumbled 10.5% after the biopharmaceutical company said it’s pausing enrollment in its ongoing study of a potential ...